23andMe to delist from Nasdaq, deregister with SEC

Core Points - 23andMe announced its decision to voluntarily delist from Nasdaq and de-register with the U.S. Securities and Exchange Commission following the acquisition of its assets by Regeneron Pharmaceuticals for $256 million [1][2] - The acquisition comes after 23andMe filed for Chapter 11 bankruptcy protection in March, indicating a significant shift in the company's financial status and operational strategy [2] Company Actions - The voluntary delisting from Nasdaq and de-registration with the SEC marks a strategic move for 23andMe as it transitions following the asset acquisition [1] - Regeneron Pharmaceuticals emerged as the winning bidder in a bankruptcy auction for 23andMe, acquiring "substantially all" of its assets [2]